OCUL
Price
$7.11
Change
+$0.70 (+10.92%)
Updated
Apr 11 closing price
Capitalization
1.13B
30 days until earnings call
VCEL
Price
$41.25
Change
-$0.65 (-1.55%)
Updated
Apr 11 closing price
Capitalization
2.07B
25 days until earnings call
Ad is loading...

OCUL vs VCEL

Header iconOCUL vs VCEL Comparison
Open Charts OCUL vs VCELBanner chart's image
Ocular Therapeutix
Price$7.11
Change+$0.70 (+10.92%)
Volume$1.59M
Capitalization1.13B
Vericel
Price$41.25
Change-$0.65 (-1.55%)
Volume$601.59K
Capitalization2.07B
OCUL vs VCEL Comparison Chart
Loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OCUL vs. VCEL commentary
Apr 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OCUL is a Hold and VCEL is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 12, 2025
Stock price -- (OCUL: $7.11 vs. VCEL: $41.25)
Brand notoriety: OCUL and VCEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OCUL: 101% vs. VCEL: 129%
Market capitalization -- OCUL: $1.13B vs. VCEL: $2.07B
OCUL [@Biotechnology] is valued at $1.13B. VCEL’s [@Biotechnology] market capitalization is $2.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $266.66B to $0. The average market capitalization across the [@Biotechnology] industry is $1.98B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OCUL’s FA Score shows that 0 FA rating(s) are green whileVCEL’s FA Score has 0 green FA rating(s).

  • OCUL’s FA Score: 0 green, 5 red.
  • VCEL’s FA Score: 0 green, 5 red.
According to our system of comparison, VCEL is a better buy in the long-term than OCUL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OCUL’s TA Score shows that 3 TA indicator(s) are bullish while VCEL’s TA Score has 4 bullish TA indicator(s).

  • OCUL’s TA Score: 3 bullish, 6 bearish.
  • VCEL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, VCEL is a better buy in the short-term than OCUL.

Price Growth

OCUL (@Biotechnology) experienced а +11.88% price change this week, while VCEL (@Biotechnology) price change was -1.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.15%. For the same industry, the average monthly price growth was -16.20%, and the average quarterly price growth was -17.21%.

Reported Earning Dates

OCUL is expected to report earnings on Aug 11, 2025.

VCEL is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+0.15% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCEL($2.07B) has a higher market cap than OCUL($1.13B). OCUL YTD gains are higher at: -16.745 vs. VCEL (-24.877). VCEL has higher annual earnings (EBITDA): 16.6M vs. OCUL (-176.14M). OCUL has more cash in the bank: 392M vs. VCEL (116M). OCUL has less debt than VCEL: OCUL (75.8M) vs VCEL (98.8M). VCEL has higher revenues than OCUL: VCEL (237M) vs OCUL (63.7M).
OCULVCELOCUL / VCEL
Capitalization1.13B2.07B55%
EBITDA-176.14M16.6M-1,061%
Gain YTD-16.745-24.87767%
P/E RatioN/A206.25-
Revenue63.7M237M27%
Total Cash392M116M338%
Total Debt75.8M98.8M77%
FUNDAMENTALS RATINGS
OCUL vs VCEL: Fundamental Ratings
OCUL
VCEL
OUTLOOK RATING
1..100
6556
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
8549
SMR RATING
1..100
9584
PRICE GROWTH RATING
1..100
8663
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OCUL's Valuation (50) in the Pharmaceuticals Other industry is somewhat better than the same rating for VCEL (89) in the Medical Specialties industry. This means that OCUL’s stock grew somewhat faster than VCEL’s over the last 12 months.

VCEL's Profit vs Risk Rating (49) in the Medical Specialties industry is somewhat better than the same rating for OCUL (85) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew somewhat faster than OCUL’s over the last 12 months.

VCEL's SMR Rating (84) in the Medical Specialties industry is in the same range as OCUL (95) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew similarly to OCUL’s over the last 12 months.

VCEL's Price Growth Rating (63) in the Medical Specialties industry is in the same range as OCUL (86) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew similarly to OCUL’s over the last 12 months.

VCEL's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as OCUL (100) in the Pharmaceuticals Other industry. This means that VCEL’s stock grew similarly to OCUL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OCULVCEL
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 17 days ago
80%
Bullish Trend 19 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 2 days ago
71%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
70%
View a ticker or compare two or three
Ad is loading...
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VCEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IGAIX37.170.77
+2.12%
American Funds Intl Gr and Inc F3
SZCAX43.95N/A
N/A
DWS Small Cap Core A
TIOSX13.88N/A
N/A
Nuveen International Opps A
MIGPX14.23N/A
N/A
Morgan Stanley Inst Global Insgt A
FEKFX15.05N/A
N/A
Fidelity Equity-Income K6

OCUL and

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with EYPT. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
+11.01%
EYPT - OCUL
54%
Loosely correlated
+12.08%
DNLI - OCUL
48%
Loosely correlated
+1.60%
BHVN - OCUL
45%
Loosely correlated
+2.86%
ELVN - OCUL
44%
Loosely correlated
+10.73%
XENE - OCUL
44%
Loosely correlated
+2.18%
More

VCEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCEL has been loosely correlated with VCYT. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VCEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCEL
1D Price
Change %
VCEL100%
-1.55%
VCYT - VCEL
52%
Loosely correlated
+5.12%
BEAM - VCEL
42%
Loosely correlated
+5.74%
ACLX - VCEL
41%
Loosely correlated
+4.39%
TECH - VCEL
40%
Loosely correlated
+2.96%
OCUL - VCEL
39%
Loosely correlated
+11.01%
More